Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06437171
PHASE4

FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

Sponsor: AAADRS Clinical Research Center

View on ClinicalTrials.gov

Summary

This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.

Official title: The Use of Exhaled Nitric Oxide as a Predictive Marker of Allergic Reactions to Oral Food Challenge and Clinical Response of Omalizumab Treatment in Subjects With Multiple Food Allergies

Key Details

Gender

All

Age Range

6 Years - Any

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2024-06-03

Completion Date

2026-12

Last Updated

2025-08-14

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

Omalizumab

Omalizumab dose and frequency based on baseline subject weight and total IgE

Locations (1)

AAADRS Clinical Research Center

Coral Gables, Florida, United States